When it comes to animal health, Canada is a small player, representing between 2-3% of the total global animal health market.  The small market size combined with stringent regulatory requirements is an important consideration for companies when deciding which markets to pursue with their products.  They are for-profit companies, and the Return on Investment is a key driver in deciding whether it makes good business sense to pursue the Canadian market at all.

To explore this further, Lauren Carde, V.P. Operations and Regulatory Affairs for Paul Dick & Associates, full-service consulting firm for the human and animal health industries, speaks with Dr. Steven Theriault, the Chief Executive Officer of Cytophage Technologies, a Canadian company that ultimately decided not to bring their products to Canada because of the regulatory burden.